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A B S T R A C T
Objective: Data on the effect of gender on the interpretation of the GHRH plus arginine stimulation test (GHRH
+ ARG test) is controversial. We validated the GHRH + ARG stimulation test in control subjects and patients
with organic or idiopathic pituitary disease and a suspicion of adult growth hormone deficiency (AGHD) using
the Immulite 2000 XPi GH assay.
Design: We studied 126 apparently healthy adults (median age 38.8 years) and 34 patients with a suspicion of
AGHD (median age 42.2 years). Identification of AGHD with the GHRH + ARG test was investigated with
commonly accepted BMI-related consensus cut-off limits for peak GH concentrations. Serum samples collected
during the GHRH+ ARG test were analysed for GH in 2014–2015. Serum IGF-1 concentrations were studied as a
reference.
Results: In 14 of 65 (22%) control males the GH peak value was below the BMI-related cut-off limits for GH
sufficiency indicating a false diagnosis of AGHD. All control females had a normal GHRH + ARG response.
Median peak GH response was significantly (p < 0.001) higher in female (39.3 μg/L) than in male controls
(21 μg/L). According to consensus cut-offs all but one young female patient had a deficient response compatible
with a diagnosis of AGHD.
Conclusions: The GH response to stimulation by GHRH+ ARG is gender-dependent, being lower in healthy
males than in females. Gender should be considered when defining cut-off limits for peak GH concentrations in
the GHRH + ARG test. The presently used BMI-related cut-off levels will lead to a significant misclassification of
males as GH deficient.
1. Introduction
Adult growth hormone deficiency (AGHD) with evidence of hy-
pothalamic-pituitary disease is recognized as a clinical entity char-
acterized by increased abdominal fat mass, decreased muscle mass,
lowered bone density and adverse effects on quality of life and cardi-
ovascular morbidity [1–3]. However, these signs and symptoms are
nonspecific, and accurate diagnosis based on laboratory tests is needed
for successful AGHD therapy.
The diagnosis of AGHD is based on measurement of serum GH in
response to pharmacological stimulation in patients with symptoms
suggestive of AGHD [4,5]. In Europe one of the preferred tests is the
GHRH + ARG test. It is well tolerated and reproducible [6–8]. Cut-off
values for the GHRH + ARG test may vary based on the controls used
[8,9]. The presently used consensus cut-off criteria for peak GH
concentrations in the GHRH + ARG test are mainly based on the study
of Corneli et al., in which the effect of gender was not addressed, and
thus the criteria are only BMI-specific [4,5,10]. The reliability and re-
producibility of pharmacological stimulation tests in the diagnosis of
GHD are still under discussion. Albeit findings have been somewhat
controversial, age and gender obviously also affect the GH response in
the GHRH + ARG test [6,8,11–14]. Furthermore, there is a significant
variation between GH results obtained by assays from different manu-
factures, which invalidates the use of common cut-off limits [15]. There
is the high risk of misclassification when using generally accepted
consensus cut-offs [16].
The purpose of this study was to validate the GHRH + ARG test and
it's cut-off limits for diagnosis of AGHD using the GH Immulite 2000 XPi
assay calibrated against the WHO standard IS 98/574. A specific aim
was to study BMI-related consensus cut-off values in the GHRH + ARG
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We recruited 119 apparently healthy controls (59 males and 60
females) through advertisement in our hospital newspaper. The con-
trols consisted of medical students, hospital personnel and their re-
latives. To be eligible, participants were required to be healthy and
without any symptoms indicative of disease. Exclusion criteria were
pregnancy and a known or suspected disease or any symptoms or signs
indicating disease or medication.
Our aim was to recruit ten females and ten males aged 20–30 years,
30–40 years, 40–50 years and 50–60 years. Enough healthy controls
were not found in the oldest group. Among the controls, five used
statins, one beta blocker, one tamsulosin and one thyroxine for hy-
pothyroidism because of thyroidectomy and vitamin B12 injections for
pernicious anaemia. No one used estrogens. We also included seven
subjects who had been referred due to fatigue but without history of
pituitary or hypothalamic disease, as controls. They had been studied
carefully with no abnormal findings in hormone concentrations and
other laboratory tests; two of them had had pituitary imaging with
normal findings. One male had type 1 diabetes and used insulin, and
another used testosterone for primary hypogonadism.
2.2. Patients with suspected GH deficiency
We studied 34 patients (20 males and 14 females) with pituitary
disease and suspicion of GH deficiency. Of these, 24 had undergone
pituitary surgery and nine pituitary radiation. Of our patients six (five
males, one female) had received radiation over ten years before testing,
and three patients (two male, one female) within ten years. The primary
diseases were: eight non-functioning pituitary adenomas, five secreting
adenomas, three craniopharyngiomas, three cysts of the Rathke pouch,
three hypophysitis, two meningeomas, one astrocytoma, one glioma,
one ependymoma, one myxomatic pseudotumor, one histiocytosis, one
Sheehan syndrome, one congenital panhypopituitarism, two idiopathic
GHD diagnosed in childhood (one with continuing secondary hypogo-
nadism) and one secondary hypogonadism. Of these patients 20 had
three, 13 had two, one had one anterior pituitary deficiency other than
of GH, and 11 patients had hypothalamic diabetes insipidus. The pa-
tients were on adequate replacement therapy of other deficiencies
during the GHRH + ARG test. Of the patients, 12 used oral estrogen
and one used transdermal estrogel.
The study was approved by the Ethical Committee of Helsinki
University Hospital, and a written informed consent was obtained from
all subjects.
3. Methods
The subjects arrived at the hospital after an overnight fast and re-
frained from strenuous exercise in the morning of the test. Women were
studied during the follicular phase of the menstrual cycle (days 7–11).
The GHRH + ARG stimulation test was started at 7.00–10.30 (median
7.30) a.m. Intravenous cannulas (i.v.) were inserted in each arm for
blood sampling and infusions. One μg/kg GHRH (GHRH(1–29), GEREF
Serono, Italy) was administered as an i.v. bolus at time 0 min, followed
by arginine (L-arginine monohydrochloride, Braun, Melsungen,
Germany) 0.5 g/kg (maximally 30 g) over 30 min. Blood samples were
drawn at −15, 0, 15, 30, 45, 60, 75 and 90 min.
Serum was separated by centrifugation and duplicate tubes were
stored frozen for 4–6 weeks at 20 °C and then at −80 °C until analysed.
During the initial phase of the study, during years 2001–2008,
serum samples were analysed by a time-resolved immunofluorometric
GH assay (AutoDELFIA, PerkinElmer, Wallac, Turku, Finland), which
was our routine method at that time. A duplicate sample from the
GHRH + ARG test was saved at −80 °C. The basal and peak samples
were reanalysed with the Immulite 2000 XPi in 2014–2015. Thus these
samples had been frozen and thawed once before analysis. In order to
evaluate the possible effect of storage on GH levels, we reanalysed 67
samples from 2001 to 2003 in 2013 by the AutoDELFIA assay. This
confirmed that there was no loss of GH during storage.
The Immulite 2000 XPi GH assay (Siemens, Healthcare Diagnostics,
Los Angeles, CA, USA) is an immunochemiluminometric assay cali-
brated against the WHO International Standard (IS) 98/574. It re-
cognizes both 22-kDa and 20-kDa hGH. The lowest reportable con-
centration was 0.05 μg/L. For statistical analyses samples with lower
concentrations were assigned a value of 0.025 μg/L.
The GH concentrations in basal and peak samples determined with
the Immulite 2000 XPi (n = 272) correlated strongly with the
AutoDELFIA results (r = 0.997, p < 0.001). The Passing-Bablok re-
gression equation for Immulite (y) vs. AutoDELFIA (x) was
y = 1.023 ∗ x + 0.01. For diagnosis of AGHD we used BMI-specific cut-
off limits (11.5 μg/L, BMI < 25 kg/m2; 8.0 μg/L, 25–30 kg/m2;
4.2 μg/L, BMI > 30 kg/m2), which have been reported in the con-
sensus statement [4,5].
Serum IGF-1 was measured during the same thawing with the
Immulite 2000 XPi. IGF-1 assay that has been calibrated against the
WHO International Reference Reagent (IRR) 87/518. IGF-1 concentra-
tions were compared with age-specific reference values provided by the
assay manufacturer.
3.1. Statistical methods
The results are expressed as median and range or mean and standard
deviation as appropriate. The non-parametric Mann-Whitney U test was
used to compare non-normally distributed continuous variables be-
tween groups and two-sample t-test to compare normally distributed
variables between groups. Spearman correlation was used to test as-
sociations between continuous variables. The difference in peak GH,
basal GH and IGF-1 values between groups was studied using analysis
of covariance after adjustment for potential confounding factors,
gender, age and BMI. Age and BMI adjusted gender difference within
groups was evaluated using analysis of covariance. Due to the positively
skewed distributions, log-transformed peak GH, basal GH and IGF-1
values were used in analysis of covariance. p-Values < 0.05 were
considered statistically significant. SPSS for Windows version, 23.0
(IBM Corp. Armonk, NY, USA) was used for all statistical analyses.
4. Results
Table 1 shows characteristics of the study population. Among con-
trol subjects there was no significant difference in age between genders,
but in males BMI was significantly higher than in females (p < 0.01).
Table 2 shows basal and peak serum GH and IGF-1 concentrations.
Among the controls, females had both higher basal and peak GH level
than males, and this gender difference remained significant after ad-
justment for age and BMI (p < 0.001). The peak GH value correlated
negatively with BMI (r =−0.56; p < 0.001) and age (r = −0.37;
p < 0.001).
All 61 female controls but only 51 of 65 males (78.5%) had peak GH
values above the BMI-related cut-off limits for GH sufficiency (Fig. 1).
Of those 14 males, who were classified as GH insufficient, three had a
BMI below 25 kg/m2, ten a BMI of 25–30 kg/m2 and one over 30 kg/m2
(Fig. 1). BMI was significantly higher in these than in the other male
controls (mean BMI 26.9 kg/m2 vs. 24.6 kg/m2 respectively,
p < 0.05). The median age of these males was 40 year (range
28.1–59.4 year) and there was no difference in age compared with the
other male controls. Serum IGF-1 concentrations in these 14 males were
within the reference ranges established by the manufacturer of the
Immulite assay.
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Among patients, females had a higher peak GH than males (median
2.2 μg/L vs. 1.4 μg/L; p < 0.01), but the difference in peak GH be-
tween genders did not remain significant after adjustment for age and
BMI (p = 0.15) (Table 2). Basal GH was also higher in females than in
males (median 0.12 μg/L vs. 0.03 μg/L; p < 0.05) and the difference
remained significant after adjustment for age and BMI. Among patients,
peak GH correlated negatively with age (r = −0.43; p < 0.05), but
not with BMI (r = 0.09; p = 0.63). Using current BMI-related cut-off
limits for diagnosis of AGHD, a 19-year-old female patient with a BMI of
33.9 kg/m2 had a peak GH response of 16.3 μg/L and was thus classi-
fied as “GH sufficient”.
The peak GH response was lower in patients than in controls
(median 1.5 μg/L; range 0.03–16.3 μg/L vs. 27.2 μg/L; 2.7–116.0 μg/L,
p < 0.001) (Table 2 and Fig. 1). Two male patients (40.7 year; 2.8 μg/
L and 44 year; 2.9 μg/L) and the above-mentioned young female had a
peak GH above the lowest value of controls (2.68 μg/L for males,
11.9 μg/L for females) (Fig. 1). All three patients had a BMI above
30 kg/m2. Basal GH and IGF-1 levels were also lower in patients than in
controls (p < 0.001) (Table 2). The differences between groups re-
mained significant after adjustment for gender, age and BMI for peak
(p < 0.001) and basal GH (p < 0.001). The difference in IGF-1 con-
centrations was also significant (p < 0.001).
There was no gender difference in serum IGF-1 concentrations in
controls or patients either before or after adjustment for age and BMI
(p = 0.20 vs. p = 0.16, respectively) (Table 2). Serum IGF-1 correlated
with peak GH both in controls (r = 0.20; p < 0.05) and patients
(r = 0.60; p < 0.001), but not with a basal GH (r = 0.14; p = 0.13
and r = 0.09; p = 0.64, respectively). The IGF-1 concentrations cor-
related with BMI in patients (r = 0.48; p < 0.01), but not in controls
(r = −0.06; p = 0.52). The serum IGF-1 concentrations were below
the age-related reference values in 25 of 34 (73.5%) patients and the
rest were within the lowest third of the reference range. Among 126
controls, six had a value below and three above the reference range.
5. Discussion
In accordance with a recent study by Deutschbein et al. [14] we
found that the peak GH values in the GHRH + ARG test are clearly
higher in healthy females than in males within the same BMI group.
With the current BMI-related cut-off limits of AGHD, all female controls
were classified as GH sufficient, whereas 22% (14/65) of the males
were misclassified as insufficient. Thus, if this gender difference is not
taken into account, which is the case in the present guidelines of AGHD
[4,5] men are at risk of being falsely diagnosed as GH deficient.
A gender difference has been demonstrated in at least three previous
studies [8,12,17] with a smaller number of healthy subjects than in the
present study. In these, the significance of the gender difference for
diagnosis of AGHD was not emphasized. So far, gender-related cut-off
limits are not in routine use. Estrogens play a role in mediating the
gender difference in GH secretion. Pulsatile GH levels have been re-
ported to be higher in the late follicular and mid-luteal phase than in
the early follicular phase [18]. A strength of our study was that all
female controls were studied during the follicular phase of the men-
strual cycle (days 7–11) and no one used estrogen.
All patients, including three patients who had received radiation
therapy within 10 years [19], but not a 19.3 years-old female with a
peak GH of 16.3 μg/L, had a GH response below the present BMI-spe-
cific cut-off limits for adult GHD. Serum IGF-1 of this patient was below
the lower reference limit. This patient had been operated for a cra-
niopharyngioma and received substitution therapy; thyroxine, hydro-
cortisone, oral estrogen and desmopressin. Oral estrogen treatment is
known to reduce serum IGF-1 concentration and increase the GH con-
centration [20]. Based on findings of high GH concentrations during
puberty, it has been suggested, that higher cut-off levels (15.1–20.3 μg/
L) should be used for diagnosis of GHD [21-23] during a transition
period between 16 and 25 years. However, the results concerning the
influence of age on the peak GH in the GHRH + ARG test are diverging:
Table 1














Age (year) 39.1 (11.3) 39.0 (11.2) 39.2 (11.5) 42.4 (11.9) 45.9 (12.1)§ 37.5 (10.2)*
Height (m) 1.74 (0.09) 1.80 (0.06) 1.67 (0.06)*** 1.70 (0.09) 1.76 (0.05)§ 1.62 (0.06)***§§
Weight (kg) 73.7 (13.0) 81.1 (10.9) 65.8 (10.2)*** 83.0 (17.7)§§§ 88.1 (16.7) 75.7 (17.0)*
BMI (kg/m2) 24.3 (3.1) 25.1 (2.9) 23.5 (3.0)** 28.6 (5.4)§§§ 28.4 (4.7) §§ 28.9 (6.4) §§
BMI (kg/m2), n
< 25 83 (66%) 36 (55%) 47 (77%) 9 (27%) 5 (25%) 4 (29%)
25–30 37 (29%) 26 (40%) 11 (18%) 13 (38%) 10 (50%) 3 (21%)
> 30 6 (5%) 3 (5%) 3 (5%) 12 (35%) 5 (25%) 7 (50%)
The statistical significance for the difference between healthy controls and patients (§p < 0.05, §§p < 0.01, §§§p < 0.001) and for the difference between males and females within
control and patient groups (*p < 0.05, **p < 0.01, ***p < 0.001).
Table 2
Peak and basal serum GH and serum IGF-1 concentrations (medians and ranges) in controls and patients analysed by Immulite 2000 XPi.























































§§§p < 0.001; the statistical significance for the difference between control and patient groups using analysis of covariance after adjustment for gender, age and BMI.
*p < 0.05, ***p < 0.001; the statistical significance for the difference between males and females within control and patient groups using analysis of covariance after adjustment for
age and BMI.
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earlier it was thought that age has no effect [6,24] but Colao et al.
proposed that the cut-off values should be based on BMI and age. The
authors suggested the following cut-off limits for subjects aged
15–25 years: 15.6 μg/L for a BMI< 25 kg/m2, 11.7 μg/L for 25–30 kg/
m2 and 8.5 μg/L for over 30 kg/m2 [13]. In that study, there was no
difference in peak GH between males and females (mean 41.2 μg/L vs.
42.6 μg/L, respectively).
Although the correlation between GH assays is generally good, there
are significant differences between some assays. Müller et al. [15]
evaluated commercially available GH immunoassays, which all except
the AutoDELFIA (IS 80/505) and BC-IRMA (IS 88/624), were calibrated
against the second International Standard for GH, WHO IS 98/574,
which is advocated in the recent consensus statement [25]. Consider-
able between-method differences were observed in mean concentra-
tions of 312 serum samples: Siemens, Immulite 2000, (5.90 μg/L);
PerkinElmer, AutoDELFIA, (5.62 μg/L); IDS, iSYS (5.28 μg/L); DiaSorin,
Liaison (4.76 μg/L); Mediagnost, ELISA (3.91 μg/L); Beckman Coulter,
UniCel Dxl 800 Access (3.91 μg/L) and Beckman Coulter, BC-IRMA
(3.19 μg/L) [15]. Thus, the interpretation of GH stimulation results is
dependent on the assay used. Our method, Immulite 2000, gave the
highest concentration. Assays recognizing both 22 kDa and 20 kDa hGH
forms are expected to give higher concentrations than methods specific
for 22 kDa GH [26].
Most patients (74%) had subnormal serum IGF-1 concentrations and
the rest of the patients had IGF-1 within the lowest third of the age-
related reference values. The biological within-subject variation for
IGF-1 is high (CV 20%) and a single serum IGF-1 measurement is not
necessarily enough [27]. There is a remarkable overlap between pa-
tients with AGHD and healthy subjects, especially in subjects over
40 years of age. Thus, a normal IGF-1 level does not rule out GHD
[4,28]. Furthermore, despite overtly suppressed GH secretion, serum
IGF-1 levels are often within the reference range for healthy obese
subjects [4]. Interestingly, despite a clear gender difference in the GH
response to GHRH + ARG, the IGF-1 levels were similar in healthy
females and males in the present study.
A strength of our study is the relatively large number of control
subjects and well-characterized male and female patients. A limitation
is the rather small number of healthy males and females with a high
BMI.
All female controls were classified as GH sufficient using the current
commonly accepted BMI-related cut-off limits, but for males those cut-
offs with Immulite 2000 XPi were too high. The higher BMI of males is
not the reason, because the difference remained after using analysis of
covariance after adjustment for age and BMI. Unfortunately the BMI
groups of males are too small to establish exact cut-offs. In the group of
normal BMI (n = 36), the cut-off is by using 2.5 percentile 9.4 µg/L
instead of 11.5 µg/L and in the overweight group (n = 26) it is about
3.5 µg/L not 8 µg/L. The obese group is very small (n = 3), according
to those results, it is around 2.7 µg/L.
In conclusion, our study shows that in addition to BMI, gender has
to be taken into account when interpreting the GHRH + ARG test and it
may be one significant and independent determinant of GH peak re-
sponse. Lower cut-off limits for peak GH concentrations have to be used
for males than for females. This may be the case also for other stimu-
lation tests e.g. the arginine alone test [17]. The presently used BMI-
related consensus cut-off levels are suitable for females, but will lead to
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